{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:59:59Z","timestamp":1778525999920,"version":"3.51.4"},"reference-count":42,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Changes of biomarkers measured soon after heart transplantation (HTx) can reflect different processes: cardiomyocyte necrosis (troponins, high-sensitivity cardiac TnT and TnI), heart function (natriuretic peptides, BNP and NT-proBNP), fibrosis (galectin-3 and ST2), and global cardiorenal risk (cystatin C). We assessed the prognostic role of hsTnT, NT-proBNP, galectin-3 and cystatin C during the early post-transplant period.<\/jats:p><jats:p>A total of 121 consecutive post-HTx patients were assessed. The main outcomes were survival, left ventricular ejection fraction (LVEF) and rejection periods. Survival was assessed after intermediate (12 months) and long periods (total follow-up during study, median of survival 763 days, IR 527\u20131038 days). LVEF was assessed 12 months after HTx. Rejection was evaluated during follow-up. We report biomarker concentrations measured 10 days and 12 months after HTx.<\/jats:p><jats:p>Ten days after HTx, cystatin C and hsTnT predicted death both under univariable and multivariable analysis. These two biomarkers along with galectin-3 were increased in patients with decreased LVEF measured 1 year after HTx. NT-proBNP did not show early prognostic power. None of the measured biomarkers predicted rejection, but hsTnT and NT-proBNP were increased significantly 12 months after HTx in patients with at least one rejection.<\/jats:p><jats:p>Cystatin C and hsTnT measured 10 days after HTx can provide prognostic information on survival and galectin-3 measured at the same time may display a relationship to heart function assessed 1 year after HTx. Further study should be carried out in a large cohort of patients.<\/jats:p>","DOI":"10.1515\/cclm-2014-1218","type":"journal-article","created":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T17:21:27Z","timestamp":1438276887000},"source":"Crossref","is-referenced-by-count":19,"title":["The role of timely measurement of galectin-3, NT-proBNP, cystatin C and hsTnT in predicting prognosis and heart function after heart transplantation"],"prefix":"10.1515","volume":"54","author":[{"given":"Janka","family":"Franekov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Ho\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Se\u010dn\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Pazdern\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark\u00e9ta","family":"Kotrbat\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zden\u011bk","family":"Kub\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton\u00edn","family":"Jabor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref191","first-page":"2015","article-title":"Long - term biological variability of galectin after heart transplantation","volume":"23","author":"Franekov\u00e1","journal-title":"Clin Chem Lab Med"},{"key":"ref251","first-page":"643","article-title":"Local expression of myocardial galectin does not correlate with its serum levels in patients undergoing heart transplantation Transplant","volume":"18","author":"Beiras","year":"2013","journal-title":"Ann"},{"key":"ref391","first-page":"2015","article-title":"Core Team language and environment for statistical computing Foundation for Statistical Computing Available from http www - project org Accessed","volume":"14","author":"May"},{"key":"ref291","first-page":"112","article-title":"Lok Klip IT Lok Bruggink - Andr\u00e9 de la Porte Badings van Wijngaarden Incremental prognostic power of novel biomarkers ( growth - differentiation factor high - sensitivity reactive protein galectin and high - sensitivity troponin - in patients with advanced","volume":"15","year":"2013","journal-title":"Am J Cardiol"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models : issues in developing models evaluating assumptions and adequacy and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"ref271","first-page":"101","article-title":"de in heart failure with preserved ejection fraction","volume":"15","author":"Boer","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"ref491","first-page":"167","article-title":"WC deFilippi AS van Elevated plasma galectin - is associated with near - term rehospitalization in heart failure : a pooled analysis of clinical trials","author":"Meijers","year":"2014","journal-title":"Am Heart J"},{"key":"ref111","first-page":"919","article-title":"Analytical evaluation of the automated galectin assay on the immunoassay instruments","volume":"26","author":"Gaze","year":"2014","journal-title":"ARCHITECT Clin Chem Lab Med"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2011.174359","article-title":"the development of heart failure after acute coronary syndrome : pilot experience from PROVE IT -","volume":"22","author":"Grandin","year":"2012","journal-title":"Clin Chem"},{"key":"ref51","first-page":"219","article-title":"van der Velde AR Prognostic value of changes in galectin levels over time in patients with heart failure : data from CORONA and COACH Fail","volume":"26","author":"Gullestad","year":"2013","journal-title":"Heart"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Developed in collaboration with the Heart Failure Association of","volume":"14","author":"McMurray","year":"2012","journal-title":"Cardiology Eur J Heart Fail"},{"key":"ref361","article-title":"Revision of the working formulation for the standardization of nomenclature in the diagnosis of heart rejection Transplant","volume":"24","author":"Stewart","year":"1990","journal-title":"Heart Lung"},{"key":"ref431","first-page":"1","article-title":"The use of biomarkers in the patient with heart failure","volume":"15","author":"Chowdhury","year":"2013","journal-title":"Curr Rep"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"de DJ in cardiac remodeling and heart failure Fail","volume":"7","author":"Boer","year":"2010","journal-title":"Curr Heart Rep"},{"key":"ref11","first-page":"101","article-title":"de in heart failure with preserved ejection fraction","volume":"15","author":"Boer","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"ref101","article-title":"Revision of the working formulation for the standardization of nomenclature in the diagnosis of heart rejection Transplant","volume":"24","author":"Stewart","year":"1990","journal-title":"Heart Lung"},{"key":"ref171","first-page":"1","article-title":"The use of biomarkers in the patient with heart failure","volume":"15","author":"Chowdhury","year":"2013","journal-title":"Curr Rep"},{"key":"ref511","first-page":"643","article-title":"Local expression of myocardial galectin does not correlate with its serum levels in patients undergoing heart transplantation Transplant","volume":"18","author":"Beiras","year":"2013","journal-title":"Ann"},{"key":"ref131","first-page":"2015","article-title":"Core Team language and environment for statistical computing Foundation for Statistical Computing Available from http www - project org Accessed","volume":"14","author":"May"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0195-668X(02)00799-6","article-title":"The logistic","volume":"24","author":"Roques","year":"2003","journal-title":"Eur Heart J"},{"key":"ref311","first-page":"219","article-title":"van der Velde AR Prognostic value of changes in galectin levels over time in patients with heart failure : data from CORONA and COACH Fail","volume":"26","author":"Gullestad","year":"2013","journal-title":"Heart"},{"key":"ref381","first-page":"150","article-title":"Disease : Improving Global Outcomes Group clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney","year":"2013","journal-title":"Work Kidney Int"},{"key":"ref141","first-page":"2015","article-title":"regression modeling strategies package version Available from http project org package rms Accessed","volume":"4","author":"Harrell"},{"key":"ref231","first-page":"167","article-title":"WC deFilippi AS van Elevated plasma galectin - is associated with near - term rehospitalization in heart failure : a pooled analysis of clinical trials","author":"Meijers","year":"2014","journal-title":"Am Heart J"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Developed in collaboration with the Heart Failure Association of","volume":"14","author":"McMurray","year":"2012","journal-title":"Cardiology Eur J Heart Fail"},{"key":"ref121","first-page":"150","article-title":"Disease : Improving Global Outcomes Group clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney","year":"2013","journal-title":"Work Kidney Int"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2011.174359","article-title":"the development of heart failure after acute coronary syndrome : pilot experience from PROVE IT -","volume":"22","author":"Grandin","year":"2012","journal-title":"Clin Chem"},{"key":"ref31","first-page":"112","article-title":"Lok Klip IT Lok Bruggink - Andr\u00e9 de la Porte Badings van Wijngaarden Incremental prognostic power of novel biomarkers ( growth - differentiation factor high - sensitivity reactive protein galectin and high - sensitivity troponin - in patients with advanced","volume":"15","year":"2013","journal-title":"Am J Cardiol"},{"key":"ref61","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2009.128397","article-title":"cardiovascular risk","author":"Taglieri","year":"2009","journal-title":"Clin Chem"},{"key":"ref221","first-page":"108","article-title":"Usefulness of plasma galectin levels in systolic heart failure to predict renal insufficiency and survival","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"ref21","first-page":"237","article-title":"de der a modifiable risk factor in heart failure","volume":"28","author":"Boer","year":"2014","journal-title":"Drugs Ther"},{"key":"ref321","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2009.128397","article-title":"cardiovascular risk","author":"Taglieri","year":"2009","journal-title":"Clin Chem"},{"key":"ref371","first-page":"919","article-title":"Analytical evaluation of the automated galectin assay on the immunoassay instruments","volume":"26","author":"Gaze","year":"2014","journal-title":"ARCHITECT Clin Chem Lab Med"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0195-668X(02)00799-6","article-title":"The logistic","volume":"24","author":"Roques","year":"2003","journal-title":"Eur Heart J"},{"key":"ref71","first-page":"128","article-title":"AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation Heart Association Task Force on practice guidelines","author":"Yancy","year":"2013","journal-title":"American Circulation"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models : issues in developing models evaluating assumptions and adequacy and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"ref281","first-page":"237","article-title":"de der a modifiable risk factor in heart failure","volume":"28","author":"Boer","year":"2014","journal-title":"Drugs Ther"},{"key":"ref481","first-page":"108","article-title":"Usefulness of plasma galectin levels in systolic heart failure to predict renal insufficiency and survival","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"ref451","first-page":"2015","article-title":"Long - term biological variability of galectin after heart transplantation","volume":"23","author":"Franekov\u00e1","journal-title":"Clin Chem Lab Med"},{"key":"ref401","first-page":"2015","article-title":"regression modeling strategies package version Available from http project org package rms Accessed","volume":"4","author":"Harrell"},{"key":"ref331","first-page":"128","article-title":"AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation Heart Association Task Force on practice guidelines","author":"Yancy","year":"2013","journal-title":"American Circulation"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"de DJ in cardiac remodeling and heart failure Fail","volume":"7","author":"Boer","year":"2010","journal-title":"Curr Heart Rep"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2014-1218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T17:49:07Z","timestamp":1691862547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2014-1218\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,1]]},"references-count":42,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1515\/cclm-2014-1218","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,1]]}}}